Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.

Journal of acquired immune deficiency syndromes (1999)

Volumn 64, Issue 4, 2013, Pages 351-359

  Rodriguez, Benigno ^a   Asmuth, David M ^b   Matining, Roy M ^b   Spritzler, John ^b   Jacobson, Jeffrey M ^b   Mailliard, Robbie B ^b   Li, Xiao Dong ^b   Martinez, Ana I ^b   Tenorio, Allan R ^b   Lori, Franco ^b   Lisziewicz, Julianna ^b   Yesmin, Suria ^b   Rinaldo, Charles R ^b   Pollard, Richard B ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS RNA;

CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; HUMAN; IMMUNIZATION; IMMUNOLOGY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; VIREMIA; VIRUS LOAD;

AIDS VACCINES; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; HUMANS; IMMUNIZATION SCHEDULE; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 84891932867     PISSN: None     EISSN: 19447884     Source Type: Journal    
DOI: None     Document Type: Article

References (0)